Mandy Jackson

Metabolic disorders biotech Vogenx sets terms for $75 million IPO $VOGX $IPO #IPO zpr.io/A9fsfXcJNdHJ

Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO $ATTO $IPO #IPO zpr.io/jyNnjBbUXVL8

Obstructive Sleep Apnea pharma Apnimed sets terms for $150 million IPO $APMD $IPO #IPO zpr.io/uZSJRczfJMDa

Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO $LTGO $IPO #IPO zpr.io/bdDvEcRAbB2g

Hypoxia-focused biotech NuvOx Therapeutics files for a $20 million IPO $NUOX $IPO #IPO zpr.io/nwkqHziYVPhZ

Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO $BLSM $IPO #IPO zpr.io/XAQEe2NR5QLL

Phase 1 immune system diseases biotech Attovia Therapeutics files for a $100 million IPO $ATTO $IPO #IPO zpr.io/qtqJ7kGQ2imq

Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO $BRVE $IPO #IPO zpr.io/nPZQidi4Fa32

@PharmaScrip @PharmaPinkSheet @INVIVOnow Hot off the presses, our Scrip/Pink Sheet/In Vivo #BIO2026 day 4 BIO Notebook. Enjoy! Now, time to rest! 😎🌴☀️ insights.citeline.com/scrip/conferen…

Here’s the @PharmaScrip @PharmaPinkSheet and @INVIVOnow free-to-read #BIO2026 day 3 BIO Notebook with insights from interviews and presentations at the meeting. Day 4 coverage still to come and more to follow in the coming days and weeks! insights.citeline.com/scrip/conferen…

The combined Scrip/Pink Sheet/In Vivo coverage of #BIO2026 from days 1 & 2 is free to read at @PharmaScrip and @PharmaPinkSheet. These daily notebooks include snapshots from interviews & panels at the meeting. insights.citeline.com/scrip/conferen…

Thank you to #BIO2026 “Betting Bold: How Smart Deals Build Biotech" panelists Rigel's Joseph Lasaga, Innoviva's Austin Hackett, Ovid's Jeff Rona and Protara's Jesse Shefferman for a great conversation this afternoon and to our audience for listening in! $RIGL $INVA $TARA $OVID

On Tuesday at 1:45-2:45 p.m. I’m talking deals at #BIO2026 again as I moderate “Building Value Through Strategic Pipeline Diversification” with dealmakers from $JNJ and @Boehringer and the CEO of $ZVRA convention.bio.org/2026-sessions-…

Picked up my badge for the @IAmBiotech BIO International Convention and I’m looking forward to moderating a panel tomorrow at 3-4 p.m. “Betting Bold: How Smart Deals Build Biotech” with executives from $INVA $RIGL $OVID & $TARA convention.bio.org/2026-sessions-…

Just imagine this flu outbreak on an aircraft carrier or submarine jam-packed with thousands of US Navy personnel. Vaccines save lives and make our military work as safely and efficiently as we need them to as we attempt to wind down a war in Iran.

Lucky no. 13 - Kardigan raised $400m tonight in its IPO, the 13th biopharma IPO in the US so far this year. $KARD businesswire.com/news/home/2026…

Cardiovascular diseases biotech Kardigan sets terms for $350 million IPO $KARD $IPO #IPO zpr.io/vBA43UPS7v7D

Cancer biotech Parabilis Medicines ups shares offered by 33% ahead of $600 million IPO $PBLS $IPO #IPO zpr.io/J2ga66fivmGy

FDA concerns about PRC2 complex inhibition & potential secondary hematologic malignancies, with both EZH2- & EED-targeting, due to Ipsen’s Tazverik, ended Fulcrum’s pociredir development & now there’s a partial hold on 2 Daiichi Sankyo valemetostat trials. insights.citeline.com/scrip/r-and-d/…